Comparing Therapeutic Approaches in Psychedelic-Assisted Therapy

Major Therapeutic Frameworks

Psychedelic-assisted therapy (PAT) does not describe a single method but rather a family of therapeutic approaches that share the use of a psychedelic substance as part of the therapeutic process. What distinguishes these approaches from simple drug administration is the structured therapeutic context — including preparation sessions before the drug session, the drug session itself conducted with professional support, and integration sessions afterward. The specific therapeutic framework used to structure this process varies considerably across research groups, clinical settings, and individual practitioners, and these differences matter for understanding how the therapy is intended to work and what kind of participants it may best serve.

The major frameworks currently in use can be broadly categorised along several dimensions: how directive vs non-directive the therapy is (whether therapists actively guide the experience or allow it to unfold); whether the approach is primarily trauma-focused, existentially focused, or transpersonally focused; how much weight is placed on the content of the psychedelic experience vs the neurobiological effects of the drug; and how extensively post-session integration is structured. Approaches also vary in the number of sessions, the dose used, whether music is used and how, the role of physical touch (such as hand-holding, a controversial but extensively discussed element of some protocols), and the training and professional background required of therapists.

Understanding these distinctions matters for several reasons. From a research perspective, it is important to know which elements of a complex intervention produce benefit — is it the drug, the therapy, the relationship with the therapist, the music, the set and setting, or their interaction? From a clinical perspective, practitioners working with different presenting problems (trauma vs depression vs existential distress in terminal illness vs addiction) may find that different frameworks are better suited to their clients' needs. And from an individual perspective, those considering participation in clinical trials or, where legal, therapeutic contexts, benefit from understanding what different approaches actually involve before choosing or being assigned to a particular framework.

MAPS Protocol vs ACE Model

The MAPS (Multidisciplinary Association for Psychedelic Studies) protocol was developed specifically for MDMA-assisted psychotherapy for PTSD and represents the most extensively clinically tested psychedelic therapy protocol in the world. It involves a dyadic therapy team (typically one male and one female therapist), three preparatory therapy sessions, two to three MDMA sessions of approximately eight hours each, and three integration sessions following each drug session. The therapeutic approach draws on a broadly non-directive, person-centred stance: therapists follow the client's lead, offering presence and support rather than interpretation or direction. The protocol explicitly avoids therapist-led processing of trauma content and instead trusts the innate healing capacity of the individual to direct what emerges during the MDMA state. Physical touch (such as holding a hand during difficult moments) is explicitly incorporated in the protocol with specific consent-based guidelines.

The ACE (Accept, Connect, Embody) model, developed by researchers at the University of California San Francisco and other institutions, offers a different framework particularly developed for psilocybin-assisted therapy. ACE is more structured in its therapeutic approach, drawing on acceptance and commitment therapy (ACT) principles: it explicitly works on acceptance of difficult emotions and experiences, deepening connection to personal values, and embodied presence. Where the MAPS protocol is broadly non-directive, ACE provides therapists with specific conceptual tools for helping clients engage with challenging material. ACE also places particular emphasis on the role of the body and somatic awareness during sessions, distinguishing it from purely cognitive or narrative-focused approaches.

A third major influence on psilocybin-assisted therapy frameworks is the approach developed at Johns Hopkins University, which draws on a broadly psychedelic-supportive, non-directive stance similar to the MAPS protocol in its deference to the patient's autonomous process, but was developed specifically for psilocybin rather than MDMA and tends to use higher doses (25–30 mg psilocybin) with extensive set and setting preparation. Johns Hopkins protocols have been used in trials for depression, smoking cessation, and alcohol use disorder. The emphasis on mystical-type experience as a mediator of therapeutic benefit — a finding that has emerged robustly across Hopkins studies — distinguishes this approach philosophically from more trauma-processing-oriented frameworks that treat the psychedelic experience as a vehicle for accessing trauma rather than as inherently transformative in its own right.

Integration Therapy Approaches

Integration therapy refers to the therapeutic work done after a psychedelic experience to help an individual make sense of, emotionally process, and practically apply what they encountered during their session. It is increasingly recognised as one of the most critical components of the overall therapeutic arc — the period during which the experiential material is translated into lasting psychological change. Different therapeutic traditions offer different tools for this work, and practitioners trained in various modalities approach integration from distinct angles.

Internal Family Systems (IFS) therapy, developed by Richard Schwartz, has emerged as a particularly popular and seemingly well-suited framework for psychedelic integration. IFS conceptualises the psyche as composed of multiple "parts" — each with its own perspective, history, and protective function — and the role of therapy as developing a relationship between the "Self" (the calm, compassionate core of the person) and these various parts. Psychedelic experiences frequently surface what IFS practitioners would recognise as exiled parts (carrying pain or shame from the past) and protective parts (managers and firefighters that developed to guard against that pain). IFS provides a coherent language and methodology for the integration conversation: helping clients understand the parts they encountered, what those parts are protecting, and how to develop a different relationship with them.

Somatic approaches to integration — including somatic experiencing (developed by Peter Levine), sensorimotor psychotherapy, and EMDR (Eye Movement Desensitisation and Reprocessing) — are also frequently employed in psychedelic integration contexts, particularly when the experience involved trauma processing or body-centred material. These approaches work with the physiological residues of trauma stored in the body and nervous system rather than focusing primarily on cognitive narrative. Breathwork modalities — including holotropic breathwork (developed by Stanislav Grof) and other techniques — occupy a unique position at the intersection of integration and standalone non-drug practice, offering altered states of consciousness that can continue the processing initiated by psychedelic sessions. Practitioners often draw eclectically from multiple modalities, tailoring their approach to individual clients.

Choosing the Right Approach

The question of which therapeutic approach is "right" for a given individual involves multiple layers of consideration. At the most basic level, most people do not freely choose their therapeutic framework — they choose a clinic, a researcher, a trial, or a therapist, and that professional or institution has its own established approach. Understanding the differences between frameworks is therefore more useful as a basis for asking informed questions and understanding what to expect than as a direct selection process for most individuals. That said, as the field matures and more diverse approaches become available, informed choice will become increasingly important.

From a presenting problem perspective, some preliminary evidence suggests that different frameworks may suit different conditions. The MAPS MDMA protocol has the strongest evidence base for PTSD specifically, and the non-directive approach may be particularly important in trauma contexts where directive interventions could feel controlling or retraumatising. Existential distress in the context of terminal illness has been most extensively studied using the Hopkins-style high-dose psilocybin approach, where the possibility of a mystical or peak experience appears therapeutically central. Treatment-resistant depression work has used a variety of frameworks with comparable initial results, suggesting that the drug itself plays a substantial role independent of the specific therapy approach.

Therapist training, experience, and relational quality likely matter as much as theoretical framework. Research on conventional psychotherapy consistently finds that the therapeutic relationship — the alliance between therapist and client — is one of the strongest predictors of therapeutic outcome across modalities. This finding likely applies in psychedelic-assisted contexts as well, where the relationship with the therapist during preparation and integration, and the sense of safety and trust during the session itself, may be central determinants of outcome. For individuals seeking integration support outside formal clinical trials, finding a therapist who has direct experience with psychedelic integration, who understands the specific territory of psychedelic experiences, and with whom a genuine therapeutic relationship can develop, may be more important than the specific modality they employ.

Frequently Asked Questions

What is the MAPS protocol for MDMA-assisted therapy?

The MAPS (Multidisciplinary Association for Psychedelic Studies) protocol is a structured therapeutic framework developed specifically for MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD). It involves a co-therapy team of two therapists (typically one male and one female), three preparatory therapy sessions to establish rapport and prepare the client for the drug session, two to three extended MDMA sessions of approximately eight hours each conducted in a clinic-like setting with music and an eye mask, and three integration sessions following each drug session. The therapeutic approach is broadly non-directive: therapists follow the client's internal process rather than directing it. The protocol completed Phase 3 clinical trials and represents the most rigorously tested psychedelic therapy protocol in existence, though FDA approval has faced regulatory challenges as of 2026.

What is the ACE model in psychedelic therapy?

The ACE model (Accept, Connect, Embody) is a therapeutic framework for psilocybin-assisted therapy developed at UCSF and related institutions. It draws on principles from acceptance and commitment therapy (ACT) to provide a structured way for therapists to support clients through psilocybin sessions. "Accept" refers to accepting difficult thoughts, emotions, and physical sensations rather than resisting them; "Connect" refers to connecting with personal values and sense of meaning; "Embody" refers to bringing awareness to somatic experience and physical presence during the session. The ACE model provides therapists with a conceptual language for active (though still largely non-directive) support during challenging moments in a session, distinguishing it from fully non-directive approaches. It has been used in psilocybin trials for depression and other indications.

What is IFS therapy in the context of psychedelic integration?

Internal Family Systems (IFS), developed by psychotherapist Richard Schwartz, is a model of mind that views the psyche as composed of multiple "parts" — each with its own perspective, history, and purpose — and a core "Self" characterised by qualities such as compassion, curiosity, and calm. IFS has become widely used in psychedelic integration because psychedelic experiences frequently surface material that maps readily onto IFS concepts: exiled parts (aspects of the self carrying pain, shame, or fear from past experiences) often appear during sessions, along with protective parts that developed to guard against contact with that pain. Integration therapists trained in IFS can help clients develop relationships with parts they encountered during their session, understand the protective logic of difficult experiences, and support the unburdening of exiled pain — using the psychedelic experience as opening the door to work that IFS can then help complete.

How does breathwork relate to psychedelic therapy?

Breathwork — particularly holotropic breathwork, developed by Stanislav Grof — occupies a unique position in the psychedelic therapy landscape. Grof, a psychiatrist who extensively researched LSD in the 1960s and 70s, developed holotropic breathwork as a non-pharmacological method for accessing non-ordinary states of consciousness after LSD became illegal. Holotropic breathwork uses accelerated breathing, evocative music, and body work to produce altered states that Grof considered phenomenologically similar to those produced by psychedelics. Many practitioners use breathwork as a complementary or preparatory practice to psychedelic therapy, or as a continuation of integration work. Some integration therapists are also trained breathwork facilitators. Breathwork is legal everywhere and offers a way to continue accessing inner-directed healing states between or after psychedelic sessions.

How long does integration typically take?

Integration does not have a fixed timeline and varies considerably depending on the depth and content of the psychedelic experience, the presenting psychological concerns, and the individual's existing capacity for psychological reflection and support. For single-session experiences without significant trauma content, active integration — where the experience continues to yield insights and require emotional processing — often spans two to six weeks. For more complex experiences, particularly those involving significant trauma processing or existential themes, integration may productively continue for six months to a year or longer. Clinical trial protocols typically include three integration sessions following each drug session over a period of several months. Many practitioners emphasise that integration is not something that is completed but rather an ongoing practice of incorporating the experience's lessons into daily life — which can continue indefinitely.

What is the difference between trauma-focused and existential approaches?

Trauma-focused approaches to psychedelic-assisted therapy centre on the processing of specific traumatic memories, emotional patterns, and somatic responses using the neuroplastic and emotionally open state induced by psychedelics to enable reprocessing of trauma that is inaccessible or too threatening in ordinary consciousness. These approaches draw on trauma therapy traditions (EMDR, somatic experiencing, psychodynamic therapy) and are most clearly exemplified by the MAPS MDMA protocol for PTSD. Existential approaches focus not on specific traumatic content but on fundamental questions of meaning, mortality, identity, and connection — and on the capacity of high-dose psychedelic experiences to produce a sense of perspective, awe, or interconnection that reorganises one's relationship to these existential concerns. Hopkins' research on psilocybin for terminal illness and depression exemplifies the existential approach, where the mystical quality of the experience is considered therapeutically central.

What are the cost differences between therapeutic approaches?

Cost differences between psychedelic therapy approaches are substantial and largely driven by regulatory context, session length, and professional requirements. Where psilocybin-assisted therapy is legal (notably Oregon in the USA, and in clinical trials), single psilocybin sessions with preparation and integration support range from approximately USD 1,000 to over USD 3,500 per session-set, with full therapeutic programmes often exceeding USD 5,000–10,000. MDMA-assisted therapy, where available through clinical contexts, is similarly expensive due to the length of sessions (eight hours) and co-therapist requirement. Ketamine-assisted therapy, which is legally available in many more jurisdictions, tends to be more accessible at USD 400–800 per session but varies widely. Breathwork, group integration sessions, and peer-support models offer significantly lower-cost alternatives, though without the pharmacological component of full psychedelic-assisted protocols.

Who decides which therapeutic approach is used?

In clinical trial contexts, the therapeutic approach is fixed by the trial protocol and participants are assigned to it upon enrolment — there is generally no individual choice of framework within a given trial. In legal therapeutic contexts (such as Oregon's Measure 109 programme), the facilitation centre or individual licensed facilitator determines the approach used, though clients can choose which centre or facilitator to work with based on their stated approach. In underground or self-guided contexts, individuals make their own decisions about framework, often working with an integration therapist independently of their psychedelic session. For those seeking integration support, the most practical approach is to seek therapists who have direct psychedelic integration experience and to ask specifically about their framework, training, and experience with presenting concerns similar to your own.

Is group therapy or individual therapy better for psychedelic integration?

Both group and individual integration therapy have distinct advantages. Individual integration therapy offers privacy, tailored attention, and the ability to explore sensitive or private material in depth. It is well-suited for trauma work, where confidentiality and individual pacing are particularly important. Group integration offers peer connection, normalisation (hearing others describe similar experiences can be profoundly validating), community, and lower cost. Research on conventional psychotherapy suggests comparable outcomes for group vs individual formats for many presenting concerns. In the psychedelic integration context, community-based organisations such as Zendo Project and various integration circles have demonstrated the value of group support. Many practitioners recommend a combination: individual integration therapy for deeper personalised work, complemented by group integration for community and shared resonance.

What if one therapeutic approach does not work?

Non-response or partial response to a particular psychedelic-assisted therapy approach is possible, just as in conventional psychotherapy. If a specific protocol does not produce anticipated benefit, several considerations are relevant. It may be that more integration time and work is needed before outcomes can be assessed — benefit sometimes continues to emerge for months after a session. It may be that a different therapeutic approach would be better suited — for example, moving from a non-directive to a more structure-supported framework, or from an existential focus to a trauma-focused approach. It is also possible that psilocybin-assisted therapy is not the appropriate intervention for a particular presenting concern or individual, and that other evidence-based treatments (CBT, EMDR, medication, or other modalities) are more appropriate. Consulting with a psychiatrist or psychologist familiar with the full range of evidence-based options is important when any particular approach does not provide adequate benefit.